{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:51:19Z","timestamp":1793998279047,"version":"4.8.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Migraine is a highly prevalent neurological disease with a substantial societal burden due to lost productivity. From a societal perspective, we assessed the cost-effectiveness of eptinezumab for the preventive treatment of migraine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An individual patient simulation of discrete competing events was developed to evaluate eptinezumab cost-effectiveness compared to best supportive care for adults in the United Kingdom with\u2009\u2265\u20094 migraine days per month and prior failure of\u2009\u2265\u20093 preventive migraine treatments. Individuals with sampled baseline characteristics were created to represent this population, which comprised dedicated episodic and chronic migraine subpopulations. Clinical efficacy, utility, and work productivity inputs were based on results from the DELIVER randomised controlled trial (NCT04418765). Timing of natural history events and treatment holidays\u2014informed by the literature\u2014were simulated to unmask any natural improvement of the disease unrelated to treatment. The primary outcomes were monthly migraine days, migraine-associated costs, quality-adjusted life years (QALYs), incremental cost-effectiveness ratio, and net monetary benefit, each evaluated over a 5-year time horizon from 2020. Secondary analyses explored a lifetime horizon and an alternative treatment stopping rule.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Treatment with eptinezumab resulted in an average of 0.231 QALYs gained at a saving of \u00a34,894 over 5 years, making eptinezumab dominant over best supportive care (i.e., better health outcomes and less costly). This result was confirmed by the probabilistic analysis and all alternative assumption scenarios under the same societal perspective. Univariate testing of inputs showed net monetary benefit was most sensitive to the number of days of productivity loss, and monthly salary.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This economic evaluation shows that from a societal perspective, eptinezumab is a cost-effective treatment in patients with\u2009\u2265\u20094 migraine days per month and for whom\u2009\u2265\u20093 other preventive migraine treatments have failed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>N\/A.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s10194-024-01749-8","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T14:01:54Z","timestamp":1713448914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivity"],"prefix":"10.1186","volume":"25","author":[{"given":"Edward","family":"Griffin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gawain","family":"Shirley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Ying","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne F.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Goadsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"issue":"1","key":"1749_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","journal-title":"Cephalalgia"},{"issue":"10258","key":"1749_CR2","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","unstructured":"GBD 2019 Diseases and Injuries Collaborators (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet 396(10258):1204\u20131222. https:\/\/doi.org\/10.1016\/S0140-6736(20)30925-9","journal-title":"Lancet"},{"key":"1749_CR3","unstructured":"Institute for Health Metrics and Evaluation (2019) GBD Compare https:\/\/vizhub.healthdata.org\/gbd-compare\/. Accessed 17 Apr 2023"},{"issue":"1","key":"1749_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s10194-021-01356-x","volume":"22","author":"O Affatato","year":"2021","unstructured":"Affatato O, Miguet M, Schi\u00f6th HB, Mwinyi J (2021) Major sex differences in migraine prevalence among occupational categories: a cross-sectional study using UK Biobank. J Headache Pain 22(1):145. https:\/\/doi.org\/10.1186\/s10194-021-01356-x","journal-title":"J Headache Pain"},{"issue":"7","key":"1749_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1046\/j.1468-2982.2003.00568.x","volume":"23","author":"TJ Steiner","year":"2003","unstructured":"Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB (2003) The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia 23(7):519\u2013527. https:\/\/doi.org\/10.1046\/j.1468-2982.2003.00568.x","journal-title":"Cephalalgia"},{"issue":"1","key":"1749_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1526-4610.2011.02046.x","volume":"52","author":"D Buse","year":"2012","unstructured":"Buse D, Manack A, Serrano D, Reed M, Varon S, Turkel C, Lipton R (2012) Headache impact of chronic and episodic migraine: results from the American migraine prevalence and prevention study. Headache 52(1):3\u201317. https:\/\/doi.org\/10.1111\/j.1526-4610.2011.02046.x","journal-title":"Headache"},{"issue":"1","key":"1749_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-020-1084-y","volume":"21","author":"DC Buse","year":"2020","unstructured":"Buse DC, Reed ML, Fanning KM, Bostic R, Dodick DW, Schwedt TJ et al (2020) Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. J Headache Pain 21(1):23. https:\/\/doi.org\/10.1186\/s10194-020-1084-y","journal-title":"J Headache Pain"},{"key":"1749_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/head.13966","author":"DC Buse","year":"2020","unstructured":"Buse DC, Reed ML, Fanning KM, Bostic RC, Lipton RB (2020) Demographics, headache features, and comorbidity profiles in relation to headache frequency in people with migraine: results of the American Migraine Prevalence and Prevention (AMPP) study. Headache. https:\/\/doi.org\/10.1111\/head.13966","journal-title":"Headache"},{"issue":"2","key":"1749_CR9","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/head.13708","volume":"60","author":"S Munjal","year":"2020","unstructured":"Munjal S, Singh P, Reed ML, Fanning K, Schwedt TJ, Dodick DW et al (2020) Most bothersome symptom in persons with migraine: results from the Migraine in America symptoms and treatment (MAST) study. Headache 60(2):416\u2013429. https:\/\/doi.org\/10.1111\/head.13708","journal-title":"Headache"},{"issue":"1","key":"1749_CR10","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/head.12168","volume":"54","author":"AB Walters","year":"2014","unstructured":"Walters AB, Hamer JD, Smitherman TA (2014) Sleep disturbance and affective comorbidity among episodic migraineurs. Headache 54(1):116\u2013124. https:\/\/doi.org\/10.1111\/head.12168","journal-title":"Headache"},{"issue":"2","key":"1749_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1524-4733.2007.00246.x","volume":"11","author":"JS Brown","year":"2008","unstructured":"Brown JS, Neumann PJ, Papadopoulos G, Ruoff G, Diamond M, Menzin J (2008) Migraine frequency and health utilities: findings from a multisite survey. Value Health 11(2):315\u2013321. https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00246.x","journal-title":"Value Health"},{"issue":"8","key":"1749_CR12","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/head.13613","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse DC, Fanning KM, Reed ML, Murray S, Dumas PK, Adams AM, Lipton RB (2019) Life with migraine: effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache 59(8):1286\u20131299. https:\/\/doi.org\/10.1111\/head.13613","journal-title":"Headache"},{"key":"1749_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s10194-016-0599-8","volume":"17","author":"C Lampl","year":"2016","unstructured":"Lampl C, Thomas H, Stovner LJ, Tassorelli C, Katsarava Z, La\u00ednez JM et al (2016) Interictal burden attributable to episodic headache: findings from the eurolight project. J Headache Pain 17:9. https:\/\/doi.org\/10.1186\/s10194-016-0599-8","journal-title":"J Headache Pain"},{"key":"1749_CR14","unstructured":"The Work Foundation (2018) Society\u2019s headache. The socioeconomic impact of migraine. https:\/\/www.lancaster.ac.uk\/media\/lancaster-university\/content-assets\/documents\/lums\/work-foundation\/SocietysHeadacheTheSocioeconomicimpactofmigraine.pdf. Accessed 17 Apr 2023."},{"key":"1749_CR15","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2147\/CEOR.S304158","volume":"13","author":"J Ford","year":"2021","unstructured":"Ford J, Nichols RM, Ye W, Tockhorn-Heidenreich A, Cotton S, Jackson J (2021) Patient-reported outcomes for migraine in the US and Europe: burden Associated with multiple preventive treatment failures. Clinico econ Outc Res. 13:647\u201360. https:\/\/doi.org\/10.2147\/CEOR.S304158","journal-title":"Clinico econ Outc Res."},{"issue":"9","key":"1749_CR16","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1177\/0333102420919098","volume":"40","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Evers S (2020) International classification of Headache disorders - ICHD-4 alpha. Cephalalgia 40(9):887\u2013888. https:\/\/doi.org\/10.1177\/0333102420919098","journal-title":"Cephalalgia"},{"issue":"7","key":"1749_CR17","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","volume":"21","author":"M Ashina","year":"2022","unstructured":"Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK et al (2022) Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 21(7):597\u2013607. https:\/\/doi.org\/10.1016\/S1474-4422(22)00185-5","journal-title":"Lancet Neurol"},{"issue":"1","key":"1749_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s10194-022-01521-w","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Goadsby PJ, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK et al (2022) Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study. J Headache Pain 23(1):153. https:\/\/doi.org\/10.1186\/s10194-022-01521-w","journal-title":"J Headache Pain"},{"key":"1749_CR19","unstructured":"EMC, Summary of product characteristics (2023) VYEPTI 100 mg concentrate for solution for infusion. https:\/\/www.medicines.org.uk\/emc\/product\/13243\/smpc. Accessed 17 Apr 2023"},{"key":"1749_CR20","unstructured":"National Institute for Health and Care Excellence (NICE) (2020) TA659: Galcanezumab for preventing migraine. https:\/\/www.nice.org.uk\/guidance\/TA659. Accessed 17 Apr 2023"},{"key":"1749_CR21","unstructured":"National Institute for Health and Care Excellence (NICE) (2021) TA682: Erenumab for preventing migraine. https:\/\/www.nice.org.uk\/guidance\/ta682. Accessed 17 Apr 2023"},{"key":"1749_CR22","unstructured":"National Institute for Health and Care Excellence (NICE) (2022) TA764: Fremanezumab for preventing migraine. https:\/\/www.nice.org.uk\/guidance\/TA764. Accessed 17 Apr 2023"},{"key":"1749_CR23","unstructured":"National Institute for Health and Care Excellence (NICE) (2023) TA871: Eptinezumab for preventing migraine. https:\/\/www.nice.org.uk\/guidance\/ta871\/. Accessed 17 Apr 2023"},{"key":"1749_CR24","unstructured":"National Institute for Health and Care Excellence (NICE) (2022) NICE health technology evaluations: the manual. https:\/\/www.nice.org.uk\/process\/pmg36\/. Accessed 17 April 2023"},{"key":"1749_CR25","unstructured":"NHS England (2022) What are integrated care systems? https:\/\/www.england.nhs.uk\/integratedcare\/what-is-integrated-care\/. Accessed 8 May 2023"},{"key":"1749_CR26","unstructured":"The King\u2019s Fund (2022) Integrated care systems explained: making sense of systems, places and neighbourhoods. https:\/\/www.kingsfund.org.uk\/publications\/integrated-care-systems-explained. Accessed 8 May 2023"},{"issue":"1","key":"1749_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12875-023-02242-y","volume":"25","author":"D Kernick","year":"2024","unstructured":"Kernick D, Kondori N, Pain A, Mount J, Appel C, Ranopa M, Gulati T (2024) Preventive treatment patterns in the adult migraine population: an observational UK study over 7 years. BMC Primary Care 25(1):34. https:\/\/doi.org\/10.1186\/s12875-023-02242-y","journal-title":"BMC Primary Care"},{"key":"1749_CR28","unstructured":"Office for National Statistics (ONS) (2021) National Life Tables: England. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/bulletins\/nationallifetablesunitedkingdom\/2018to2020. Accessed 17 Apr 2023"},{"issue":"6","key":"1749_CR29","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40273-014-0147-9","volume":"32","author":"J Karnon","year":"2014","unstructured":"Karnon J, Haji Ali Afzali H (2014) When to use discrete event simulation (DES) for the economic evaluation of health technologies? A review and critique of the costs and benefits of DES. Pharmacoeconomics 32(6):547\u2013558. https:\/\/doi.org\/10.1007\/s40273-014-0147-9","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"1749_CR30","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS (2021) The American headache society consensus statement: update on integrating new migraine treatments into clinical practice. Headache 61(7):1021\u20131039. https:\/\/doi.org\/10.1111\/head.14153","journal-title":"Headache"},{"issue":"4\u20135","key":"1749_CR31","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/03331024211046617","volume":"42","author":"B Raffaelli","year":"2022","unstructured":"Raffaelli B, Terhart M, Overeem LH, Mecklenburg J, Neeb L, Steinicke M, Reuter U (2022) Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia 42(4\u20135):326\u2013334. https:\/\/doi.org\/10.1177\/03331024211046617","journal-title":"Cephalalgia"},{"issue":"1","key":"1749_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013\u20092022 update. J Headache Pain 23(1):67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x","journal-title":"J Headache Pain"},{"issue":"8","key":"1749_CR33","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1212\/WNL.0b013e31820d8af2","volume":"76","author":"A Manack","year":"2011","unstructured":"Manack A, Buse DC, Serrano D, Turkel CC, Lipton RB (2011) Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology 76(8):711\u2013718. https:\/\/doi.org\/10.1212\/WNL.0b013e31820d8af2","journal-title":"Neurology"},{"issue":"8","key":"1749_CR34","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/aje\/kwq464","volume":"173","author":"J Roy","year":"2011","unstructured":"Roy J, Stewart WF (2011) Methods for estimating remission rates from cross-sectional survey data: application and validation using data from a national migraine study. Am J Epidemiol 173(8):949\u2013955","journal-title":"Am J Epidemiol"},{"issue":"1","key":"1749_CR35","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s10194-017-0787-1","volume":"18","author":"D Serrano","year":"2017","unstructured":"Serrano D, Lipton RB, Scher AI, Reed ML, Stewart WF, Adams AM, Buse DC (2017) Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain 18(1):101. https:\/\/doi.org\/10.1186\/s10194-017-0787-1","journal-title":"J Headache Pain"},{"issue":"10","key":"1749_CR36","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41582-021-00544-2","volume":"17","author":"DN Krause","year":"2021","unstructured":"Krause DN, Warfvinge K, Haanes KA, Edvinsson L (2021) Hormonal influences in migraine \u2014 interactions of oestrogen, oxytocin and CGRP. Nat Reviews Neurol 17(10):621\u2013633. https:\/\/doi.org\/10.1038\/s41582-021-00544-2","journal-title":"Nat Reviews Neurol"},{"issue":"5","key":"1749_CR37","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, Group obotAA (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68(5):343\u2013349. https:\/\/doi.org\/10.1212\/01.wnl.0000252808.97649.21","journal-title":"Neurology"},{"issue":"1","key":"1749_CR38","doi-asserted-by":"publisher","first-page":"34e1","DOI":"10.1016\/j.ajog.2011.02.059","volume":"205","author":"AJ Pokoradi","year":"2011","unstructured":"Pokoradi AJ, Iversen L, Hannaford PC (2011) Factors associated with age of onset and type of menopause in a cohort of UK women. Am J Obstet Gynecol 205(1):34e1\u20133413. https:\/\/doi.org\/10.1016\/j.ajog.2011.02.059","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"1749_CR39","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/gme.0000000000000736","volume":"24","author":"P Paramsothy","year":"2017","unstructured":"Paramsothy P, Harlow SD, Nan B, Greendale GA, Santoro N, Crawford SL et al (2017) Duration of the menopausal transition is longer in women with young age at onset: the multiethnic study of women\u2019s Health across the Nation. Menopause 24(2):142\u2013149. https:\/\/doi.org\/10.1097\/gme.0000000000000736","journal-title":"Menopause"},{"issue":"1","key":"1749_CR40","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12883-021-02123-w","volume":"21","author":"D Kudrow","year":"2021","unstructured":"Kudrow D, Cady RK, Allan B, Pederson SM, Hirman J, Mehta LR, Schaeffler BA (2021) Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurol 21(1):126. https:\/\/doi.org\/10.1186\/s12883-021-02123-w","journal-title":"BMC Neurol"},{"key":"1749_CR41","unstructured":"GSK (1998) Migraine-Specific Quality-of-Life Questionannaire (MSQ Version 2.1). https:\/\/eprovide.mapi-trust.org\/instruments\/migraine-specific-quality-of-life-questionnaire. Accessed July 2023"},{"issue":"3","key":"1749_CR42","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jval.2011.12.007","volume":"15","author":"PJ Gillard","year":"2012","unstructured":"Gillard PJ, Devine B, Varon SF, Liu L, Sullivan SD (2012) Mapping from disease-specific measures to health-state utility values in individuals with migraine. Value Health 15(3):485\u2013494. https:\/\/doi.org\/10.1016\/j.jval.2011.12.007","journal-title":"Value Health"},{"key":"1749_CR43","unstructured":"EuroQol (2019) EQ-5D-5L User Guide. https:\/\/euroqol.org\/publications\/user-guides\/. Accessed July 2023 2023"},{"key":"1749_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14737167.2023.2219898","volume":"23","author":"L Jonsson","year":"2023","unstructured":"Jonsson L, Regnier SA, Kymes S, Awad SF, Talon B, Lee XY, Goadsby PJ (2023) Estimating treatment effects on health utility scores for patients living with migraine: a post hoc analysis of the DELIVER trial. Expert Rev Pharmacoecon Outcomes Res 23:1\u20137. https:\/\/doi.org\/10.1080\/14737167.2023.2219898","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"1749_CR45","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/ene.15670","volume":"30","author":"PJ Goadsby","year":"2023","unstructured":"Goadsby PJ, Barbanti P, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK et al (2023) Eptinezumab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures. Eur J Neurol 30(4):1089\u20131098. https:\/\/doi.org\/10.1111\/ene.15670","journal-title":"Eur J Neurol"},{"key":"1749_CR46","unstructured":"NICE (2022) British National Formulary (BNF). https:\/\/bnf.nice.org.uk. Accessed 17 Apr 2023"},{"key":"1749_CR47","unstructured":"National Institute for Health and Care Excellence (NICE) (2010) Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor. https:\/\/www.nice.org.uk\/guidance\/ta195. Accessed 7 July 2023"},{"key":"1749_CR48","unstructured":"NHS England. 2019\/20 National Cost Collection Data Publication 2021 [updated 27 July 2022]. Available from: https:\/\/www.england.nhs.uk\/publication\/2019-20-national-cost-collection-data-publication\/. Accessed 17 Apr 2023"},{"key":"1749_CR49","volume-title":"Amanda. Unit Costs of Health & Social Care 2020","author":"LAB Curtis","year":"2020","unstructured":"Curtis LAB (2020) Amanda. Unit Costs of Health & Social Care 2020. PSSRU University of Kent, Kent Academic Repository"},{"issue":"17 Supplement 2","key":"1749_CR50","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1212\/WNL.0000000000202965","volume":"100","author":"P Barbanti","year":"2023","unstructured":"Barbanti P, Awad SF, Regnier SA, Lee X, Goadsby PJ (2023) Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: Post hoc analysis of the DELIVER trial (P13-12.012). Neurology 100(17 Supplement 2):3020. https:\/\/doi.org\/10.1212\/WNL.0000000000202965","journal-title":"Neurology"},{"issue":"5","key":"1749_CR51","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","volume":"19","author":"M Linde","year":"2012","unstructured":"Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barr\u00e9 J, Katsarava Z et al (2012) The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 19(5):703\u2013711. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03612.x","journal-title":"Eur J Neurol"},{"key":"1749_CR52","unstructured":"Office for National Statistics (ONS) (2022) Earnings and employment from Pay As You Earn Real Time Information, UK: June 2022. https:\/\/www.ons.gov.uk\/employmentandlabourmarket\/peopleinwork\/earningsandworkinghours\/bulletins\/earningsandemploymentfrompayasyouearnrealtimeinformationuk\/june2022. Accessed 7 July 2023."},{"key":"1749_CR53","unstructured":"Office for National Statistics (ONS): Labour market overview, UK (2020) https:\/\/www.ons.gov.uk\/employmentandlabourmarket\/peopleinwork\/employmentandemployeetypes\/bulletins\/uklabourmarket\/january2020. Accessed 7 July 2023"},{"issue":"1","key":"1749_CR54","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s10194-022-01492-y","volume":"23","author":"S Khanal","year":"2022","unstructured":"Khanal S, Underwood M, Naghdi S, Brown A, Duncan C, Matharu M, Mistry H (2022) A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine. J Headache Pain 23(1):122. https:\/\/doi.org\/10.1186\/s10194-022-01492-y","journal-title":"J Headache Pain"},{"issue":"10","key":"1749_CR55","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1177\/0333102418796842","volume":"38","author":"M Sussman","year":"2018","unstructured":"Sussman M, Benner J, Neumann P, Menzin J (2018) Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives. Cephalalgia 38(10):1644\u20131657. https:\/\/doi.org\/10.1177\/0333102418796842","journal-title":"Cephalalgia"},{"issue":"3","key":"1749_CR56","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40273-020-00996-2","volume":"39","author":"R Mahon","year":"2021","unstructured":"Mahon R, Lang A, Vo P, Huels J, Cooney P, Danyliv A et al (2021) Cost-effectiveness of erenumab for the preventive treatment of migraine in patients with prior treatment failures in Sweden. Pharmacoeconomics 39(3):357\u2013372. https:\/\/doi.org\/10.1007\/s40273-020-00996-2","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1749_CR57","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1332\/174426410x482999","volume":"6","author":"I Shemilt","year":"2010","unstructured":"Shemilt I, James T, Marcello M (2010) A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy 6(1):51\u201359. https:\/\/doi.org\/10.1332\/174426410x482999","journal-title":"Evid Policy"},{"key":"1749_CR58","unstructured":"National Institute for Health and Care Excellence (NICE) (2012) TA260: Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. https:\/\/www.nice.org.uk\/guidance\/TA260. Accessed 17 Apr 2023"},{"issue":"Suppl 2","key":"1749_CR59","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/head.12505_2","volume":"55","author":"RB Lipton","year":"2015","unstructured":"Lipton RB, Silberstein SD (2015) Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache 55(Suppl 2):103\u201322. https:\/\/doi.org\/10.1111\/head.12505_2. quiz 23\u20136","journal-title":"Headache"},{"issue":"19","key":"1749_CR60","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2018) Effect of Fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19):1999\u20132008","journal-title":"JAMA"},{"key":"1749_CR61","unstructured":"Fund (2020) TKs: Integrated care systems explained: making sense of systems, places and neighbourhoods. https:\/\/www.kingsfund.org.uk\/publications\/integrated-care-systems-explained. Accessed"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01749-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01749-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01749-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T14:02:19Z","timestamp":1713448939000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01749-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1749"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01749-8","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"assertion":[{"value":"22 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Edward Griffin is an independent health economist contracted to H. Lundbeck A\/S or one of its affiliates through Edward Griffin Consulting Ltd (UK).Gawain Shirley, Xin Ying Lee, and Susanne F. Awad are employees of H. Lundbeck A\/S or one of its subsidiary companies.Alok Tyagi reports, over the last 36 months, participation on a Data Safety Monitoring Board or Advisory Board\u00a0for Lundbeck.Peter J. Goadsby reports, over the last 36 months, grants from Celgene and Kallyope, and personal fees from Aeon Biopharma, AbbVie, Amgen, eNeura, CoolTech LLC, Dr Reddys, Eli-Lilly and Company, Epalex, Linpharma, Lundbeck, Man&Science, Novartis, Pfizer, Sanofi, Satsuma, Shiratronics, and Teva Pharmaceuticals, and personal fees for advice through Gerson Lehrman Group, Guidepoint, SAI Med Partners, Vector Metric, and fees for educational materials from CME Outfitters, and publishing royalties or fees from Massachusetts Medical Society, Oxford University Press, UptoDate and Wolters Kluwer, and a patent magnetic stimulation for headache (No. WO2016090333 A1) assigned to eNeura without fee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}